A single-center experience of EMA/CO chemotherapy for high -risk gestational trophoblastic neoplasia: Induction low-dose cisplatin and etoposide chemotherapy improves outcome.

被引：0
|
作者：
Alifrangis, C.
Agarwal, R.
Short, D.
Savage, P.
Seckl, M.
机构：
[1] Univ London Imperial Coll Sci Technol & Med, Dept Med Oncol, London, England
[2] Univ London Imperial Coll Sci Technol & Med, Ovarian Canc Act Res Ctr, London, England
[3] Charing Cross Hosp, Trophoblast Dis Serv, London, England
[4] Charing Cross Hosp, Trophoblast Dis Ctr, London, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.5024
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5024
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Human chorionic gonadotropin (hCG) regression normograms for patients with high-risk gestational trophoblastic neoplasia treated with EMA/CO (etoposide, methotrexate, actinomycin D, cyclophosphamide and vincristine) chemotherapy
    Lybol, C.
    Westerdijk, K.
    Sweep, F. C. G. J.
    Ottevanger, P. B.
    Massuger, L. F. A. G.
    Thomas, C. M. G.
    ANNALS OF ONCOLOGY, 2012, 23 (11) : 2903 - 2906
  • [22] Low-dose Immune Tolerance Induction in Hemophilia: A Single-Center Experience
    Zulfikar, Bulent
    Koc, Basak
    Ozdemir, Nihal
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2019, 41 (06) : E355 - E358
  • [23] LOW-DOSE IMMUNE TOLERANCE INDUCTION IN HEMOPHILIA: A SINGLE-CENTER EXPERIENCE
    Messadi, W.
    Cherif, N.
    HAEMOPHILIA, 2020, 26 : 131 - 131
  • [24] Effectiveness and toxicity of first-line methotrexate chemotherapy in low-risk postmolar gestational trophoblastic neoplasia: The New England Trophoblastic Disease Center experience
    Maesta, Izildinha
    Nitecki, Roni
    Horowitz, Neil S.
    Goldstein, Donald P.
    Segalla Moreira, Marjory de Freitas
    Elias, Kevin M.
    Berkowitz, Ross S.
    GYNECOLOGIC ONCOLOGY, 2018, 148 (01) : 161 - 167
  • [25] Risk-adapted chemotherapy of germ cell tumors with carboplatin, etoposide and bleomycin for low-risk and cisplatin, etoposide and ifosfamide for high-risk patients - A single-center study
    Tscherry, G
    Jacky, E
    Jost, LM
    Stahel, RA
    ONCOLOGY, 2000, 59 (02) : 110 - 117
  • [26] Single-center experience: comparison of reduced intensive chemotherapy and low-dose cytarabine treatment as remission induction in older age aml cases
    Yikilmaz, A. Senturk
    Akinci, S.
    Bakanay, S.
    Dilek, I.
    LEUKEMIA RESEARCH, 2019, 85 : S41 - S42
  • [27] Outcomes for relapsed versus resistant low risk gestational trophoblastic neoplasia following single-agent chemotherapy
    Jareemit, Nida
    Horowitz, Neil S.
    Goldstein, Donald P.
    Berkowitz, Ross S.
    Elias, Kevin M.
    GYNECOLOGIC ONCOLOGY, 2020, 159 (03) : 751 - 757
  • [28] Resistance to multiple agent chemotherapy including cisplatin after chronic low-dose oral etoposide administration in gestational choriocarcinoma
    Okamoto, T
    Goto, S
    GYNECOLOGIC AND OBSTETRIC INVESTIGATION, 2001, 52 (02) : 139 - 141
  • [29] Single-center experience with advanced liposarcoma (LPS): Overall survival (OS), prognostic factors and chemotherapy outcome.
    Cornillie, Jasmien
    Van Cann, Thomas
    Vandeweyer, Raf
    Wozniak, Agnieszka
    Debiec-Rychter, Maria
    Sciot, Raf
    Hompes, Daphne
    Schoffski, Patrick
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [30] Comparison of clinical outcome of low-dose and high-dose rabbit antithymocyte globulin induction therapy in renal transplantation: A single-center experience
    Yang, Ji-wei
    Wang, Jian-ning
    Men, Tong-yi
    Zhang, Xiao-ming
    Li, Xian-duo
    Shen, Bin
    Li, Guang-yun
    Chen, Dong-dong
    ANNALS OF TRANSPLANTATION, 2014, 19 : 277 - 282
12345